Supplementary Figures S1-S10 from NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma

Figure S1 - Sensitivity of NB cell lines to allosteric SHP2 inhibitors. Figure S2 - Sensitivity of NB cell lines to catalytic SHP2 inhibitors. Figure S3 - Sensitivity to SHP2 inhibitors in isogenic NB cells with exogenous PTPN11 mutations. Figure S4 - NRAS status determines sensitivity to SHP2 and MAPK inhibition. Figure S5 - MAPK inhibitors sensitize NB cells to SHP099 and II-B08. Figure S6 - SHP2 inhibitors are synergistic with trametinib and other MAPK inhibitors. Figure S7 - MAPK inhibitors synergize with SHP2 inhibitors in ALK-mutant NB cells. Figure S8 - Assessment of drug tolerability for SHP099 and trametinib in vivo. Figure S9 - Pre-clinical assessment of SHP099 plus trametinib in NRAS-mutant NB xenografts. Figure S10 - Pre-clinical assessment of SHP099 plus ulixertinib in NRAS-mutant NB xenografts.